Editas, based in Cambridge, Massachusetts, has been given a $120M investment to advance genome editing.
Don Seiffert of the Boston Business Journal joined necn to discuss.
Read the full BBJ article here.
Editas, based in Cambridge, Massachusetts, has been given a $120M investment to advance genome editing.
Don Seiffert of the Boston Business Journal joined necn to discuss.
Read the full BBJ article here.